Indian patent granted for SPONTAN® and ROXUS® formulation technology
LTR Pharma Limited (ASX: LTP) says the Indian Patent Office has formally granted Patent No. 605429, titled Formulations and Methods for Treating Erectile Dysfunction. The announcement was made on 09 November 2026.
The granted claims protect defined formulation characteristics of the intranasal technology supporting the Company’s SPONTAN® and ROXUS® products.
The grant represents a further milestone in the Company’s international intellectual property strategy, supporting its ongoing clinical development and commercialisation programs.
LTR Pharma Executive Chairman, Lee Rodne
“The grant of this patent in India is a positive milestone for LTR Pharma… We are pleased with the scope of the granted claims and the additional protection they provide for our intranasal formulation technology…”
When big ASX news breaks, our subscribers know first
Patent protection runs to May 2041
The key facts of the grant are:
- Patent No. 605429
- Patent protection extends to May 2041, subject to applicable maintenance requirements and continued validity
- Covers the intranasal formulation technology supporting SPONTAN® and ROXUS®
SPONTAN® and ROXUS® are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less.
The final Phase II study, run by independent CRO Southern Star Research, compared SPONTAN against a 20 mg oral vardenafil tablet and completed the pharmacokinetic dataset the FDA requested at its 2025 Pre-IND meeting.
Mr Rodne said protecting intellectual property remains an important part of the strategy as the Company advances its clinical and commercial programs.
The commercial side of the strategy took shape in July 2026, when a U.S. telehealth distribution agreement with Shed Holdings converted an earlier term sheet into a binding contract with a 150,000-unit first-year volume commitment.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors getting FREE breaking ASX news delivered to their inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to be first to know when market-moving healthcare announcements land.